Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme trial - Author Response to Letter to the Editor

Aldéric M Fraslin1, Anne Aupérin1, Caroline Even2

  • 1Biostatistics and Epidemiology Unit, Gustave Roussy, Oncostat 1018 INSERM, labeled Ligue Contre le Cancer, University Paris-Saclay, Villejuif, France.

Abstract

No abstract available in PubMed .